相似文献
1
Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
JAMA Oncol. 2018 May 1;4(5):739-742. doi: 10.1001/jamaoncol.2018.0049.
2
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
3
Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Lung Cancer. 2018 Oct;124:154-159. doi: 10.1016/j.lungcan.2018.08.007. Epub 2018 Aug 8.
4
[The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Zhonghua Jie He He Hu Xi Za Zhi. 2018 Oct 12;41(10):778-782. doi: 10.3760/cma.j.issn.1001-0939.2018.10.006.
5
Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.
Oncotarget. 2017 Jul 11;8(28):45807-45824. doi: 10.18632/oncotarget.17416.
6
Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.
Pulmonology. 2019 Sep-Oct;25(5):306-309. doi: 10.1016/j.pulmoe.2019.04.005. Epub 2019 Jun 7.
7
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11.
8
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor ()-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.
Cancer Res Treat. 2017 Jan;49(1):10-19. doi: 10.4143/crt.2016.058. Epub 2016 May 3.
9
Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Lung Cancer. 2013 Sep;81(3):435-439. doi: 10.1016/j.lungcan.2013.05.021. Epub 2013 Jul 1.
10
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Oncotarget. 2016 Oct 4;7(40):65185-65195. doi: 10.18632/oncotarget.11218.
引用本文的文献
1
Comparative analysis of first-generation epidermal growth factor receptor inhibitors combined with chemotherapy versus third-generation epidermal growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis.
Front Pharmacol. 2025 Aug 14;16:1586332. doi: 10.3389/fphar.2025.1586332. eCollection 2025.
2
What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review.
Front Pharmacol. 2025 Aug 11;16:1572115. doi: 10.3389/fphar.2025.1572115. eCollection 2025.
3
Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations.
Appl Clin Genet. 2025 Jul 31;18:153-164. doi: 10.2147/TACG.S531337. eCollection 2025.
4
Elevated plasma HSP90α as a prognostic marker in EGFR-mutant non-small cell lung cancer.
Oncol Lett. 2025 Jul 22;30(4):457. doi: 10.3892/ol.2025.15203. eCollection 2025 Oct.
5
Prediction of the efficacy and clinical prognosis of first-line EGFR-tyrosine kinase inhibitors in non-small cell lung cancer patients based on ΔCt values derived from the super-amplification refractory mutation system (ARMS): a real-world retrospective study.
J Thorac Dis. 2025 Jun 30;17(6):3897-3911. doi: 10.21037/jtd-2025-97. Epub 2025 Jun 25.
6
[Analysis of Risk Factors for Meningeal Metastasis in Patients
with Lung Adenocarcinoma Following Non-surgical Interventions].
Zhongguo Fei Ai Za Zhi. 2025 Apr 20;28(4):267-280. doi: 10.3779/j.issn.1009-3419.2025.101.06.
7
Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC.
Ann Med. 2025 Dec;57(1):2493766. doi: 10.1080/07853890.2025.2493766. Epub 2025 Apr 25.
8
Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring 21 L858R mutation.
Glob Med Genet. 2025 Feb 19;12(2):100051. doi: 10.1016/j.gmg.2025.100051. eCollection 2025 Jun.
9
A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with mutation-positive non-small cell lung cancer.
Cancer Pathog Ther. 2024 Jun 21;3(2):135-146. doi: 10.1016/j.cpt.2024.06.004. eCollection 2025 Mar.
10
Unravelling the complexity of -mutated lung adenocarcinoma: a unique case report with histological transformations and co-alteration acquisition.
Transl Lung Cancer Res. 2025 Feb 28;14(2):639-648. doi: 10.21037/tlcr-24-707. Epub 2025 Feb 27.
本文引用的文献
1
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
2
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.
3
Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.
Cancer Lett. 2016 Jan 28;370(2):324-31. doi: 10.1016/j.canlet.2015.11.005. Epub 2015 Nov 12.
4
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.
J Clin Oncol. 2015 Jun 10;33(17):1958-65. doi: 10.1200/JCO.2014.58.1736. Epub 2015 Apr 20.
5
Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
JAMA. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314.
6
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
Zotero 插件